Home Page

 
2024 Voxmedia Satellite Symposium Image

Addressing Challenges:
Best Practices for DOAC Reversal in Intracranial Hemorrhage

Tuesday, October 15, 2024

Lunch:       12:00 PM - 12:15 PM PT
Symposium:  12:15 PM - 1:15 PM PT


Manchester Grand Hyatt San Diego
Ballroom: Cortez Hill ABC
1 Market Place
San Diego, California

Chair: Truman J. Milling, Jr., MD

Faculty: Anne Alexandrov, PhD, AGACNP-BC, ANVP-BC, CCRN, FAAN
               Paul Dobesh, PharmD
               Joshua Goldstein, MD, PhD

Registration for this program is now closed.

 
Program Overview:

Direct oral anticoagulants (DOACs) have become widely used for the prevention and treatment of venous thromboembolism, stroke prevention in atrial fibrillation, and management of patients with coronary artery disease or peripheral artery disease. Large clinical trials have demonstrated that DOACs are as effective and safer than warfarin; DOACs are now widely recommended by guidelines. Despite their superior safety, a small percentage of patients suffer intracranial hemorrhage, a devastating injury with high morbidity and mortality. Specific agents that reverse anticoagulation with factor Xa inhibition and with oral direct thrombin inhibition have demonstrated effectiveness in clinical trials and are now preferred therapies in guidelines and statements from the American Heart Association/ American Stroke Association (endorsed by multiple societies including the Neurocritical Care Society) and the American College of Cardiology Expert Consensus Decision Pathway. In this symposium, an expert multidisciplinary faculty will provide insights into and interpretations of clinical data, and challenging cases will reinforce key elements of prudent management of major bleeding in patients taking DOACs and experiencing intracranial hemorrhage.

Educational Objectives: 

  • Interpret clinical evidence with a specific reversal agent targeting dabigatran
  • Explain clinical trial data for a specific reversal agent for factor Xa inhibition
  • Describe critical considerations in managing the patient experiencing intracranial hemorrhage while receiving a direct oral anticoagulant (DOAC)


  • Target Audience: 
    This educational activity is intended for clinicians managing patients experiencing intracranial hemorrhage.

    Accreditation & Credit Designation:

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Voxmedia LLC designates this live activity for a maximum of 1.0 AMA PRA Category Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1.0 Credits through its reciprocity agreements.

    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits ™ from organizations accredited by the ACCME.

    Educational Grant:
    Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

    Disclosure Statement:
    Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.